Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Accumulated Expenses (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Other Accumulated Expenses for 10 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 4.62% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Sep 2025, up 4.62% year-over-year, with the annual reading at $363000.0 for FY2024, 68.21% down from the prior year.
  • Other Accumulated Expenses hit $1.5 million in Q3 2025 for Aptevo Therapeutics, up from $948000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.6 million in Q3 2021 to a low of $30000.0 in Q2 2022.
  • Historically, Other Accumulated Expenses has averaged $1.2 million across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 96.96% in 2022 and later soared 2386.67% in 2023.
  • Year by year, Other Accumulated Expenses stood at $2.1 million in 2021, then plummeted by 47.17% to $1.1 million in 2022, then increased by 3.63% to $1.1 million in 2023, then tumbled by 68.21% to $363000.0 in 2024, then surged by 311.57% to $1.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for APVO at $1.5 million in Q3 2025, $948000.0 in Q2 2025, and $1.1 million in Q1 2025.